Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163727 | 0.87 | GRM2 (0.51) | LRRK2GRM2CYSLTR1MRGPRX4MAPT | |
| SCHEMBL481208 | 0.85 | LRRK2 (0.45) | LRRK2GRM2CYSLTR1MRGPRX4MAPT | |
| SCHEMBL481620 | 0.85 | MAPT (0.48) | LRRK2MRGPRX4MAPTL3MBTL1CYP2C9 | |
| SCHEMBL481236 | 0.83 | CYSLTR1 (0.52) | GRM2CYSLTR1MAPTL3MBTL1CYP2C9 | |
| SCHEMBL2940441 | 0.80 | MRGPRX4 (0.54) | GRM2CYSLTR1MRGPRX4MAPTL3MBTL1 | |
| SCHEMBL3173109 | 0.79 | GRM2 (0.68) | LRRK2GRM2CYSLTR1MRGPRX4MAPT | |
| Hydrochloric Acid SCHEMBL2949438 | 0.79 | MRGPRX4 (0.53) | GRM2CYSLTR1MRGPRX4MAPTL3MBTL1 | |
| SCHEMBL8264022 | 0.78 | GRM2 (0.43) | GRM2CYSLTR1MRGPRX4MAPTL3MBTL1 | |
| SCHEMBL27686285 | 0.78 | MAPT (0.64) | GRM2CYSLTR1MRGPRX4MAPTL3MBTL1 | |
| SCHEMBL481038 | 0.78 | LRRK2 (0.38) | LRRK2GRM2CYSLTR1MRGPRX4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101955470-B | Potentiators of glutamate receptors | LILLY CO ELI | 2012-06-13 | — | — | CN | disclosed |
| EP-2441762-A1 | Potentiators of Glutamate Receptors | Eli Lilly and Company (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-1817301-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2012-02-01 | — | — | EP | disclosed |
| CN-101955470-A | Glutamate receptor potentiators | LILLY CO ELI | 2011-01-26 | — | — | CN | disclosed |
| US-7816523-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| CN-101061106-B | Glutamate receptor potentiators | LILLY CO ELI | 2010-09-29 | — | — | CN | disclosed |
| US-7803938-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| CN-101061106-A | Glutamate receptor potentiators | LILLY CO ELI (US) | 2007-10-24 | — | — | CN | disclosed |
| EP-1817301-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006057870-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | GRM1, GRIN1, GRM2 | LRRK2 1851/4885GRM2 3/4885CYSLTR1 85/4885 |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | LRRK2 1116/4885GRM2 8/4885CYSLTR1 144/4885 |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | LRRK2 1116/4885GRM2 8/4885CYSLTR1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.